Abstract
The liver represents the major site of drug metabolism in humans. The developmental changes that occur in the liver's metabolic activity during fetal life and in the perinatal period are at the basis of the varied sensitivity of human newborns to many drugs. The decreased capacity of the fetal and newborn liver to metabolize, detoxify, and excrete drugs - total cytochrome P450 content in the fetal liver being 30% to 60% of adult values - may explain the prolonged actions of many drugs in the newborn, as well as less their potential toxicity. On the other hand, the low levels of phase I (activation) enzymes, producing more polar reactive and often toxic metabolites, could explain the lower incidence of adverse effects of some drugs reported in newborns. Moreover, the greater capacity of newborns to synthesize glutathione is at the basis of their ability in inactivating many toxic metabolites. Here we review the acute and chronic liver toxicity due to the most widely used drugs in the neonate. We will discuss in detail the biochemical profile of the fetal and neonatal liver, and the toxic metabolites formed during the metabolism of the most widely used drugs in the neonate. The histological picture of liver disease related to the therapeutic use of drugs will be discussed, with particular emphasis on the mode of cell death involved in hepatitis induced by different drugs most frequently utilized in the neonatal intensive care units.
Keywords: Drugs, hepatotoxicity, human newborn, DILI, cytochrome P-450, liver, perinatal, glutathione, activation, metabolites.
Current Medicinal Chemistry
Title:A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Volume: 19 Issue: 27
Author(s): G. Faa, J. Ekstrom, M. Castagnola, Y. Gibo, G. Ottonello and V. Fanos
Affiliation:
Keywords: Drugs, hepatotoxicity, human newborn, DILI, cytochrome P-450, liver, perinatal, glutathione, activation, metabolites.
Abstract: The liver represents the major site of drug metabolism in humans. The developmental changes that occur in the liver's metabolic activity during fetal life and in the perinatal period are at the basis of the varied sensitivity of human newborns to many drugs. The decreased capacity of the fetal and newborn liver to metabolize, detoxify, and excrete drugs - total cytochrome P450 content in the fetal liver being 30% to 60% of adult values - may explain the prolonged actions of many drugs in the newborn, as well as less their potential toxicity. On the other hand, the low levels of phase I (activation) enzymes, producing more polar reactive and often toxic metabolites, could explain the lower incidence of adverse effects of some drugs reported in newborns. Moreover, the greater capacity of newborns to synthesize glutathione is at the basis of their ability in inactivating many toxic metabolites. Here we review the acute and chronic liver toxicity due to the most widely used drugs in the neonate. We will discuss in detail the biochemical profile of the fetal and neonatal liver, and the toxic metabolites formed during the metabolism of the most widely used drugs in the neonate. The histological picture of liver disease related to the therapeutic use of drugs will be discussed, with particular emphasis on the mode of cell death involved in hepatitis induced by different drugs most frequently utilized in the neonatal intensive care units.
Export Options
About this article
Cite this article as:
Faa G., Ekstrom J., Castagnola M., Gibo Y., Ottonello G. and Fanos V., A Developmental Approach to Drug-induced Liver Injury in Newborns and Children, Current Medicinal Chemistry 2012; 19 (27) . https://dx.doi.org/10.2174/092986712803306385
DOI https://dx.doi.org/10.2174/092986712803306385 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
Current Drug Metabolism Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening Clinical Pharmacology of Systemic Analgesics in Neonates
Current Drug Therapy Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Progesterone: Indications for the Prevention of Preterm Birth
Current Women`s Health Reviews Coarctation of the Aorta - The Current State of Surgical and Transcatheter Therapies
Current Cardiology Reviews Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Neonatal Ultrasound in Transport
Current Pediatric Reviews Renal Development: A Complex Process Dependent on Inductive Interaction
Current Pediatric Reviews Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Drug Metabolizing Enzymes in the Perinatal and Neonatal Period: Differences in the Expression and Activity
Current Drug Metabolism Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Editorial (Thematic Issue: Cardiovascular Drug Therapy in Paediatric Age: From Metabolomics to Clinical Practice)
Current Medicinal Chemistry Structural Chromosome Abnormalities Associated with Obesity: Report of Four New Subjects and Review of Literature
Current Genomics Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates
Current Pediatric Reviews